
Acquisitions16 Nov 2026, 09:10 pm
Sai Parenterals to Acquire Majority Stake in Bion Therapeutics
AI Summary
Sai Parenterals Limited announced its Board of Directors has approved the acquisition of a majority stake in Bion Therapeutics India Private Limited (Bion) through its wholly owned subsidiary, SP Analytics Private Limited. Bion, a Hyderabad-based branded formulations prescription business, will become a step-down subsidiary upon deal completion, expected by month-end. The transaction will be an all-cash deal, with funding support provided by SP Analytics utilizing IPO proceeds earmarked for General Corporate Purposes and debt. Bion reported a turnover of ₹28.22 Cr for the half-year ended September 30, 2026. The acquisition is intended to be undertaken on an arm's-length basis.
Key Highlights
- Sai Parenterals to acquire majority stake in Bion Therapeutics via subsidiary.
- Bion Therapeutics is a Hyderabad-based branded formulations prescription business.
- Deal is an all-cash transaction, expected to close by November 30, 2026.
- Funding will utilize IPO proceeds for General Corporate Purposes and debt.
- Bion reported ₹28.22 Cr turnover for H1 FY27.
Price Impact
More from SAIPARENT